A Dual Macrophage Targeting Nanovector for Delivery of Oligodeoxynucleotides To Overcome Cancer-Associated Immunosuppression
Source abstract
Abstract
To overcome cancer-associated immunosuppression, we prepared a dual-targeting vector to deliver CpG oligodeoxynucleotides (ODN) to macrophages. The dual-targeting system composed of mannosylated carboxymethyl chitosan (MCMC)/hyaluronan (HA) for macrophage targeting and protamine sulfate for ODN complexation was prepared by self-assembly. The effects of ODN delivery on immune cells was studied in J774A.1 cells. Due to the enhanced delivery efficiency, the dual-targeting delivery system exhibits a higher immune stimulatory activity compared with the monotargeting delivery system containing either MCMC or HA, resulting in a dramatically enhanced secretion of proinflammatory cytokines and a successful shift to activated macrophages (M1). Besides macrophages, the influence of the delivery system on tumor cells (MCF-7) was also investigated. In MCF-7 cells, the increased expressions of nuclear transcription factor-κB (NF-κB), PIK3R3, and phosphorylated protein kinase B (p-Akt) caused by activated NF-κB and phosphoinositide 3-kinase/Akt signalings were observed. Nevertheless, upregulated Fas as well as Fas ligand (FasL) may induce Fas/FasL-mediated apoptosis, which results in the increased expressions of caspases in tumor cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Biomedical Polymers of Ministry of Education, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, People’s Republic of China
Funding
National Natural Science Foundation of China
References (67)
Show source-provided references
1. 10.1038/nature1067310.1038/nature10673 ↗
2. 10.1038/nature1203410.1038/nature12034 ↗
3. 10.1016/j.it.2015.02.00410.1016/j.it.2015.02.004 ↗
4. 10.1038/srep1427310.1038/srep14273 ↗
5. 10.1016/j.addr.2015.11.00910.1016/j.addr.2015.11.009 ↗
6. 10.1016/j.jconrel.2017.03.39510.1016/j.jconrel.2017.03.395 ↗
7. 10.1038/srep1663210.1038/srep16632 ↗
8. 10.1002/jcb.2589510.1002/jcb.25895 ↗
9. 10.1146/annurev.immunol.20.100301.06484210.1146/annurev.immunol.20.100301.064842 ↗
10. 10.1016/j.addr.2008.12.00810.1016/j.addr.2008.12.008 ↗
11. 10.1038/nri132910.1038/nri1329 ↗
12. 10.1002/anie.20150138010.1002/anie.201501380 ↗
13. 10.1038/sj.onc.121091110.1038/sj.onc.1210911 ↗
14. 10.1093/infdis/jit03610.1093/infdis/jit036 ↗
15. 10.1038/nature0720510.1038/nature07205 ↗
16. 10.1016/j.tvjl.2015.04.01510.1016/j.tvjl.2015.04.015 ↗
17. 10.1126/science.274.5288.78410.1126/science.274.5288.784 ↗
18. 10.1038/nrd292610.1038/nrd2926 ↗
19. 10.1530/ERC-12-039410.1530/ERC-12-0394 ↗
20. 10.1002/wnan.142110.1002/wnan.1421 ↗
21. 10.1016/j.msec.2016.03.04510.1016/j.msec.2016.03.045 ↗
22. 10.1186/s13104-017-2380-810.1186/s13104-017-2380-8 ↗
23. 10.1016/j.ijpharm.2015.09.06210.1016/j.ijpharm.2015.09.062 ↗
24. 10.1021/bc100436y10.1021/bc100436y ↗
25. 10.1002/adma.20150631210.1002/adma.201506312 ↗
26. 10.1016/j.nano.2015.08.00410.1016/j.nano.2015.08.004 ↗
27. 10.1016/j.jconrel.2015.11.00810.1016/j.jconrel.2015.11.008 ↗
28. 10.1039/C7CC01128H10.1039/C7CC01128H ↗
29. 10.1021/acs.bioconjchem.6b0067510.1021/acs.bioconjchem.6b00675 ↗
30. 10.1016/j.xphs.2017.03.02810.1016/j.xphs.2017.03.028 ↗
31. 10.1016/j.biomaterials.2016.09.03110.1016/j.biomaterials.2016.09.031 ↗
32. 10.1021/bc300611b10.1021/bc300611b ↗
33. 10.1073/pnas.131315211010.1073/pnas.1313152110 ↗
34. 10.1016/j.jconrel.2014.11.03310.1016/j.jconrel.2014.11.033 ↗
35. 10.1021/nn305466z10.1021/nn305466z ↗
36. 10.1016/j.biomaterials.2013.10.00310.1016/j.biomaterials.2013.10.003 ↗
37. 10.1371/journal.pone.016915410.1371/journal.pone.0169154 ↗
38. 10.1038/srep0053410.1038/srep00534 ↗
39. 10.1039/C5NR02240A10.1039/C5NR02240A ↗
40. 10.1002/adfm.20130234710.1002/adfm.201302347 ↗
41. 10.1039/C6CC09280B10.1039/C6CC09280B ↗
42. 10.1016/j.jconrel.2013.08.02110.1016/j.jconrel.2013.08.021 ↗
43. 10.1016/j.mtchem.2017.01.00610.1016/j.mtchem.2017.01.006 ↗
44. 10.1002/mabi.20160019510.1002/mabi.201600195 ↗
45. 10.1016/j.ijpharm.2016.10.06510.1016/j.ijpharm.2016.10.065 ↗
46. 10.2147/IJN.S8877410.2147/IJN.S88774 ↗
47. 10.1016/j.msec.2016.12.07210.1016/j.msec.2016.12.072 ↗
48. 10.1016/j.ijpharm.2016.10.00710.1016/j.ijpharm.2016.10.007 ↗
49. 10.1016/j.biomaterials.2007.12.02510.1016/j.biomaterials.2007.12.025 ↗
50. 10.1016/j.ijpharm.2016.04.03610.1016/j.ijpharm.2016.04.036 ↗
51. 10.1002/adhm.20160101210.1002/adhm.201601012 ↗
52. 10.1016/j.jconrel.2016.11.01210.1016/j.jconrel.2016.11.012 ↗
53. 10.1021/acs.chemmater.6b0373810.1021/acs.chemmater.6b03738 ↗
54. 10.1021/jacs.6b1138210.1021/jacs.6b11382 ↗
55. 10.1002/anie.20150981010.1002/anie.201509810 ↗
56. 10.1002/smll.20160233910.1002/smll.201602339 ↗
57. 10.2217/nnm-2016-011710.2217/nnm-2016-0117 ↗
58. 10.1172/JCI3153710.1172/JCI31537 ↗
59. 10.1016/j.biomaterials.2014.10.01710.1016/j.biomaterials.2014.10.017 ↗
60. 10.1038/ni102810.1038/ni1028 ↗
61. 10.1016/S1471-4906(03)00139-X10.1016/S1471-4906(03)00139-X ↗
62. 10.1038/sj.onc.120995410.1038/sj.onc.1209954 ↗
63. 10.4049/jimmunol.168.9.471110.4049/jimmunol.168.9.4711 ↗
64. 10.1172/JCI1199110.1172/JCI11991 ↗
65. 10.1038/cmi.2013.1410.1038/cmi.2013.14 ↗
66. 10.3389/fimmu.2017.0040310.3389/fimmu.2017.00403 ↗
67. 10.3748/wjg.v11.i22.344610.3748/wjg.v11.i22.3446 ↗